Cadrenal Therapeutics (CVKD) Long-Term Deferred Tax (2022 - 2025)

Cadrenal Therapeutics has reported Long-Term Deferred Tax for 3 years, with the latest figure at $3.2 million in Q4 2025.

• Quarterly Long-Term Deferred Tax rose 24.39% year-over-year to $3.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.2 million (up 24.39% YoY) and the FY2025 annual result came in at $3.2 million, up 24.39% from the prior year.
• Long-Term Deferred Tax improved to $3.2 million in Q4 2025 per CVKD's latest filing, from $2.6 million in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $3.2 million in Q4 2025 and troughed at $532000.0 in Q4 2022.
• A 3-year average of $2.1 million and a median of $2.6 million in 2024 frame the typical range for Long-Term Deferred Tax.
• The widest YoY moves for Long-Term Deferred Tax: up 24.39% in 2025, down 24.39% in 2025.
• Over 3 years, Long-Term Deferred Tax stood at $532000.0 in 2022, then surged by 381.77% to $2.6 million in 2024, then climbed by 24.39% to $3.2 million in 2025.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $3.2 million, $2.6 million, and $532000.0 for Q4 2025, Q4 2024, and Q4 2022 respectively.